Top Markets
#1 EXOD EXOD +56.80%
#2 Glidr Glidr +35.94%
#3 Bedrock Bedrock +20.06%
#4 Cysic Cysic +18.33%
#5 Fabric Protocol Fabric Protocol +13.41%
#6 Nockchain Nockchain +11.94%
#7 Perle Perle +8.19%
#8 stake.link stake.link +8.12%
#9 Arowana Arowana +7.88%
#10 Cap Cap +7.72%
Coin of the day
EXOD EXOD
Settings
Language
ENGLISH
Currency
USD
Theme
Anatara Lifesciences Ltd Anatara Lifesciences Ltd

Anatara Lifesciences Ltd

ANR
Rank in Stocks #37961
Anatara Lifesciences Ltd is an Australian enterprise focused on researching,... Anatara Lifesciences Ltd is an Australian enterprise focused on researching, developing, and commercializing scientifically-validated therapies for digestive system ailments affecting both humans and animals. Its product portfolio includes Gastrointestinal ReProgramming (GRP), a proprietary blend combining bromelain with other evidence-based ingredients, specifically formulated to target the underlying issues of human gastrointestinal conditions such as irritable bowel syndrome and inflammatory bowel disease. The firm also offers 3FDC, designed to address anxiety, stress, or depression. In the animal health sector, Anatara provides Detach for treating diarrhea in piglets, BONIFF as an enhanced dry feed formulation for weaned piglets, and ANR-pf, a unique additive for poultry drinking water. This company was founded in 2010 and is headquartered in Carlton, Australia.
Share Price
$0.00634756
Last synced: 2026-08-14
Market Cap
$1.32M
Change (1 day)
0.00%
Change (1 year)
39.40%
Country
AU
Trade Anatara Lifesciences Ltd (ANR)

Category

Healthcare
P/E ratio for Anatara Lifesciences Ltd (ANR)
P/E ratio as of 2026 TTM: 0
According to Anatara Lifesciences Ltd latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Anatara Lifesciences Ltd from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.